National Screening Institute (NSI) has the exclusive worldwide rights to oxidized LDL and malondialdehyde (MDA)-modified LDL antibodies and corresponding technology developed by Professor Paul Holvoet at the University of Leuven, Belgium.
What we have to offer: We provide antibodies useful for the development and production of clinical assays for the detection of oxLDL (4E6) and MDA-modified LDL (1H11) through proprietary, exclusive license arrangement.
Test kits are available for clinical use. NSI test kits are manufactured and distributed by Mercodia AB located in Uppsala, Sweden. About 400,000 patients have been evaluated by pharmaceutical companies and research organizations using Mercodia’s sandwich microtiter plate assay. While the pharmaceutical studies are confidential, circa 400 articles/posters have been published.
Clinical use by physicians: Quest Diagnostics runs the oxLDL assay on an automated microtiter system. It should be noted that mail-in tests do not require special specimen handling. Additional information is available at Quest Diagnostics.